SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

KURA

Kura Oncology, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed6d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor KOMZIFTI prescription growth trajectory and new account expansion in coming quarters; watch for darlifarnib registrational study initiation in 1H 2027 and ASH 2026 presentations for ziftomenib combination data.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

KURA drug pipeline →

darlifarnib

● Neutral Named in this press release
Impact
Phase
Phase 1
Time to market
Likely 4-6+ years if successful; still in Phase 1 with registrational Phase 3 planned for 2028 at the earliest
Next catalyst
None dated

What to watchInvestors should watch the KCRS 2026 oral presentation on July 24 and the virtual investor call on July 27 for updated long-term Phase 1a durability data in ccRCC. The program is too early for binary positioning, the real value inflection points (Phase 1b randomization data, Phase 3 start in 2028, and the daraxonrasib combo entering the clinic in early 2027) are 12+ months away. KURA is a multi-asset company with an approved product, so darlifarnib is one of several value drivers.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$7.73
T+0 close · Nov 10, 2026 · via day close
Latest settled
−3.88%
T+1 · $7.43
Vs SPY
−3.53%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $7.73entry
  2. T+1 · 5d ago −3.88%α −3.53% · $7.43
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology reported Q3 2026 results with KOMZIFTI net product revenue of $13.9M, up 53% sequentially, and a net loss of $70.2M ($0.78 per share) versus consensus EPS of -$0.81. The company also announced FDA alignment on a darlifarnib registrational study and a $300M Oberland Capital financing facility.

Key Financial Metrics

EPS
−$0.78
est −$0.81 · +3.7%
Revenue
$22.8M
est $23.9M · -4.4% · +10.1% YoY
Rating
in line
Guidance
$40M-$45M
maintained

Key Facts

  • KOMZIFTI net product revenue $13.9M in Q3 2026, up 53% from Q2 2026
  • Net loss $70.2M ($0.78 per share) vs consensus EPS -$0.81
  • Total revenue $22.8M (product $13.9M + collaboration $8.9M)
  • Cash and investments $492.1M as of Sep 30, 2026
  • FDA alignment on ~40-patient darlifarnib monotherapy registrational study in HRAS-mutant salivary gland cancer
  • Oberland Capital financing agreement provides up to $300M in potential funding
  • Collaboration revenue guidance updated to $40M-$45M for 2026
  • Eight ziftomenib abstracts accepted at ASH 2026 including two oral presentations

Financial Impact

KOMZIFTI product revenue $13.9M; net loss $70.2M; cash $492.1M; collaboration revenue guidance $40M-$45M for 2026

revenuenet losscash positioncollaboration revenue

Risk Factors

  • KOMZIFTI differentiation syndrome boxed warning and safety profile may limit commercial uptake
  • Cash burn rate remains high with $492.1M cash vs $667.2M at year-end 2025
  • Darlifarnib registrational study is early-stage with regulatory and enrollment risks
  • Collaboration revenue declining ($8.9M vs $20.8M year ago) and guidance lowered

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3400190

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Viewing Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026